Jazz Pharmaceuticals, Inc. (JAZZ) Reports In-Line Q3 EPS; Guides Above the Street
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q3 EPS of $0.94, in-line with the analyst estimate of $0.94. Revenue for the quarter came in at $73.3 million versus the consensus estimate of $72.03 million.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.
Jazz Pharmaceuticals, Inc. sees FY2011 EPS of $3.45-$3.50, versus the consensus of $3.44.